• iWALK

  Participated · Series D · Sep 2012

  iWalk is a pioneer and leader in Personal Bionics whose core product line is built on proprietary BiOM technology. The first commercially available solution, the BiOM Ankle System, emulates calf muscle and Achilles tendon function to provide powered plantar flexion and a more natural gait for people with limb loss. BiOM is intended to enable natural, normalized and personalized movement so users can return to work and daily activities faster. The company plans to use recent funding to further develop and commercialize a series of Personal Bionics products and to expand its global sales and support infrastructure. iWalk’s solutions are currently available domestically through a network of Certified Bionics Centers, VA Medical Centers and the Department of Defense. Founded in 2006 by Dr. Hugh Herr, the company is headquartered in Bedford, Mass., and has received support from the U.S. Department of Veterans Affairs, the U.S. Army’s TATRC and several venture firms. iWalk is developing a self-contained robotic prosthetic ankle intended to advance powered prostheses. The company is based in Cambridge, Mass. and was founded in 2006 by MIT Media Lab professor Hugh Herr. In August 2009 it received $20m of a $21m Series B round to support development of its device. The Series B funds were provided by Cambridge-based General Catalyst Partners and New York-based WFD Ventures LLC. This round follows a $3.7m Series A and brings iWalk’s total funding to over $23.7m. The financing is presented in the articles as a Series B equity round to accelerate product development.

• BioScale

  Participated · Equity · Jun 2010

  BioScale develops protein measurement and analysis technologies, including its AMMP assay technology and ViBE platform. The company was founded in 2002 by CEO Mark Lundstrom and three interdisciplinary MIT professors. It has assembled development, engineering, manufacturing and an industry-seasoned commercial team to launch its products into pharmaceutical, biotech, life science, and bioprocess markets. BioScale is also pursuing partnering for diagnostic and specialty applications. The company recently established a new 30,000 sq. ft. global headquarters and manufacturing site in Lexington, Massachusetts. Per SEC filings, BioScale raised $5.2 million in convertible debt from 37 separate investors. BioScale Inc. is a Cambridge, MA-based life science company that develops, manufactures and promotes an innovative protein analytics technology. The company develops the ViBE protein analytics systems, which enable ultra-sensitive detection and quantitation of proteins in complex samples. ViBE systems are intended for use in research, clinical, bioprocessing, patient point-of-care and personalized medicine applications. BioScale secured $25M in its recent funding round. The financing will enable the company to expand manufacturing operations and bring the ViBE systems into the market. Investors in the round include lead investor Morningside Venture and existing partners New Science Ventures, WFD Ventures, F2 Ventures, and other individual investors.

No current team members are available.